Cocrystal Pharma Inc expected to post a loss of 50 cents a share - Earnings Preview
09/05/2025 15:21
Cocrystal Pharma Inc COCP.OQ COCP.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Cocrystal Pharma Inc is for a loss of 50 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Cocrystal Pharma Inc is $8.00, above its last closing price of $1.57. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.47 | -0.53 | -0.32 | Beat | 39.6 |
| Sep. 30 2024 | -0.57 | -0.57 | -0.49 | Beat | 14 |
| Jun. 30 2024 | -0.49 | -0.48 | -0.53 | Missed | -11.2 |
| Mar. 31 2024 | -0.54 | -0.54 | -0.39 | Beat | 27.8 |
| Dec. 31 2023 | -0.58 | -0.60 | -0.44 | Beat | 26.3 |
| Sep. 30 2023 | -0.50 | -0.53 | -0.41 | Beat | 22.6 |
| Jun. 30 2023 | -0.53 | -0.58 | -0.41 | Beat | 29.3 |
| Mar. 31 2023 | -0.59 | -0.67 | -0.64 | Beat | 5.2 |
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway